search
Back to results

ESWL Versus ESWL and Endoscopic Treatment

Primary Purpose

Pancreatitis

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
extracorporeal shock wave lithotripsy
endoscopic drainage of the main pancreatic duct
Analgesics
Sponsored by
Changhai Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pancreatitis focused on measuring Extracorporeal Shock Wave lithotripsy(ESWL), Endoscopic Retrograde Cholangiopancreatography(ERCP), chronic pancreatitis, pain relief

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • painful chronic pancreatitis(abdominal pain attack during the preceding 12 months);
  • at least 1 calcified stone greater than 5 mm in one of its axes in the cephalic or corporeal portion of the main pancreatic duct with upstream duct dilation;
  • no ERCP or ESWL carried out before admission

Exclusion Criteria:

  • suspected to have malignant tumors;
  • history of pancreatic surgery or gastrojejunostomy (Billroth II);
  • pancreatic collection greater than 2 cm in diameter at magnetic resonance or CT scan;
  • age below 18 years;
  • pregnancy or lactation;
  • refuse to write informed consent

Sites / Locations

  • Changhai HospitalRecruiting
  • Shanghai Changhai HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

ESWL alone

ESWL combined with ERCP

Arm Description

Patients in this group would be treated with extracorporeal shock wave lithotripsy only. Otherwise, extra endoscopic procedures will be carried out in case of continuous and aggravated pain. Analgesics will be administrated as needed and recorded.

People in this group would be treated with ESWL followed be endoscopic drainage of the main pancreatic duct in 48 hours. Analgesics will be administrated as needed and recorded.

Outcomes

Primary Outcome Measures

Change from baseline pain score as accessed by izbichi pain score at 12 month
Whether pain is relieved depends on the change of Izbicki pain score at the baseline and 12 months after the procedure(ERCP alone or ERCP combined with ERCP). Izbicki pain score is composed of 4 parts, that is frequency of pain attacks(daily counts for 100, several times a week counts for 75, several times a month counts for 50, several times a year counts for 25 and several times a year counts for 0), VAS(subjective evaluation of pain by patients from no pain which is 0 points to imaginative maximum of pain which is 100 points), analgesic medication(morphine consumption is 100, buprenorphine is 80, pethidine is 20, tramaldol is 15, metamizole is 3 and acetylsalicylacid is 1) and time of disease-related inability to work(permanet is 100, ≤1 month is 50, ≤1 week is 25 and no inability to work during the last year is 0). Each part counts for 100 points in all.

Secondary Outcome Measures

exocrine function of the pancreas through determination of fecal elastase as assessed by fecal elastase kit
Pancreatic exocrine function insufficiency(PEI) is defined as fecal elastase <200 μg/g. The result wii be divided into 4 conditions, that is exocrine function normal, PEI develop, PEI resolve, PEI persist.
clearance of pancreatic stones
Clearance of pancreatic stone is regarded as complete when clearance rate is more than 90%, partial is regarded as 50% to 90%, the rest is unsuccessful.
decompression rate of the pancreatic duct as the change of pancreatic duct diameter assessed by S-MRCP

Full Information

First Posted
September 5, 2016
Last Updated
May 30, 2018
Sponsor
Changhai Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02971475
Brief Title
ESWL Versus ESWL and Endoscopic Treatment
Official Title
Extracorporeal Shock Wave Lithotripsy Versus Extracorporeal Shock Wave Lithotripsy Combined With Endoscopic Treatment for Painful Calcified Chronic Pancreatitis
Study Type
Interventional

2. Study Status

Record Verification Date
May 2018
Overall Recruitment Status
Unknown status
Study Start Date
November 2016 (Actual)
Primary Completion Date
May 2019 (Anticipated)
Study Completion Date
July 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Changhai Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The study wants to compare ESWL alone with ESWL and endoscopic drainage of the MPD for treatment of pain in chronic pancreatitis.
Detailed Description
The combination mode of ESWL and ERCP is an established method of treatment of painful obstructive calcified chronic pancreatitis. However, the investigators notice that patients after ESWL alone in calcified CP is followed by spontaneous elimination of stone fragments and pain relief. Inui reported that 40% of 555 patients spontaneous eliminate stone fragments. Dumonceau found that combining systematic endoscopy with ESWL adds to the cost of patient care, without improving the outcome of the pancreatic pain. So the investigators design such a prospective and randomized controlled trial. People diagnosed with uncomplicated painful chronic pancreatitis and calcifications obstructing the MPD will be randomly assigned to the ESWL or endoscopy group according to a table of random numbers. ESWL will be performed in all patients using a electromagnetic lithotriptor. ESWL sessions will be repeated if necessary, until stone fragmentation is obtained. Patients in the endoscopy group will undergo endoscopy in 48 hours with possible stent insertion. In the ESWL group, if pain continues or aggravates, endoscopic drainage of the MPD will be carried out. Follow-up will consists of telephone interview1 after treatment and clinical examination every 6 months thereafter. Data collected will include clinical presentation, ESWL, endoscopic and surgical procedures, life quality. In addition, S-MRCP will be performed 6 months after treatment. Blood glucose, insulin, stool elastase will be taken each clinical examination.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatitis
Keywords
Extracorporeal Shock Wave lithotripsy(ESWL), Endoscopic Retrograde Cholangiopancreatography(ERCP), chronic pancreatitis, pain relief

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
62 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ESWL alone
Arm Type
Experimental
Arm Description
Patients in this group would be treated with extracorporeal shock wave lithotripsy only. Otherwise, extra endoscopic procedures will be carried out in case of continuous and aggravated pain. Analgesics will be administrated as needed and recorded.
Arm Title
ESWL combined with ERCP
Arm Type
Active Comparator
Arm Description
People in this group would be treated with ESWL followed be endoscopic drainage of the main pancreatic duct in 48 hours. Analgesics will be administrated as needed and recorded.
Intervention Type
Procedure
Intervention Name(s)
extracorporeal shock wave lithotripsy
Other Intervention Name(s)
ESWL
Intervention Description
People in this group would be treated with ESWL only.
Intervention Type
Procedure
Intervention Name(s)
endoscopic drainage of the main pancreatic duct
Other Intervention Name(s)
ERCP
Intervention Description
People in this group would be treated with ESWL followed be endoscopic drainage in 48 hours.
Intervention Type
Drug
Intervention Name(s)
Analgesics
Intervention Description
Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.
Primary Outcome Measure Information:
Title
Change from baseline pain score as accessed by izbichi pain score at 12 month
Description
Whether pain is relieved depends on the change of Izbicki pain score at the baseline and 12 months after the procedure(ERCP alone or ERCP combined with ERCP). Izbicki pain score is composed of 4 parts, that is frequency of pain attacks(daily counts for 100, several times a week counts for 75, several times a month counts for 50, several times a year counts for 25 and several times a year counts for 0), VAS(subjective evaluation of pain by patients from no pain which is 0 points to imaginative maximum of pain which is 100 points), analgesic medication(morphine consumption is 100, buprenorphine is 80, pethidine is 20, tramaldol is 15, metamizole is 3 and acetylsalicylacid is 1) and time of disease-related inability to work(permanet is 100, ≤1 month is 50, ≤1 week is 25 and no inability to work during the last year is 0). Each part counts for 100 points in all.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
exocrine function of the pancreas through determination of fecal elastase as assessed by fecal elastase kit
Description
Pancreatic exocrine function insufficiency(PEI) is defined as fecal elastase <200 μg/g. The result wii be divided into 4 conditions, that is exocrine function normal, PEI develop, PEI resolve, PEI persist.
Time Frame
12 months
Title
clearance of pancreatic stones
Description
Clearance of pancreatic stone is regarded as complete when clearance rate is more than 90%, partial is regarded as 50% to 90%, the rest is unsuccessful.
Time Frame
12 months
Title
decompression rate of the pancreatic duct as the change of pancreatic duct diameter assessed by S-MRCP
Time Frame
12 months
Other Pre-specified Outcome Measures:
Title
complication rate
Description
Complications involve pancreatitis, hemorrhage, perforation, infection and steinstrasse.
Time Frame
1 months
Title
endocrine function as assessed by the combination of fasting blood glucose, insulin, C peptide, glycosylated hemoglobin
Description
As mentioned earlier, the result of pancreatic endocrine function can also be divided into 4 parts similar to that of pancreatic exocrine function.
Time Frame
12 months
Title
treatment-related cost from initial treatment to the end of the study(12 months)
Time Frame
12 months
Title
life quality as assessed by SF-36 questionnaire
Time Frame
12 months
Title
BMI in kg/m^2
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: painful chronic pancreatitis(abdominal pain attack during the preceding 12 months); at least 1 calcified stone greater than 5 mm in one of its axes in the cephalic or corporeal portion of the main pancreatic duct with upstream duct dilation; no ERCP or ESWL carried out before admission Exclusion Criteria: suspected to have malignant tumors; history of pancreatic surgery or gastrojejunostomy (Billroth II); pancreatic collection greater than 2 cm in diameter at magnetic resonance or CT scan; age below 18 years; pregnancy or lactation; refuse to write informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zhao-shen Li
Email
zhaoshen-li@hotmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Zhuan Liao
Email
liaozhuan@smmu.edu.cn
Facility Information:
Facility Name
Changhai Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200433
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yang-Yang Qian, MD
Facility Name
Shanghai Changhai Hospital
City
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhao-shen Li
Email
zhaoshen-li@hotmail.com
First Name & Middle Initial & Last Name & Degree
Zhuan Liao
Email
liaozhuan@smmu.edu.cn
First Name & Middle Initial & Last Name & Degree
Liang-hao Hu
First Name & Middle Initial & Last Name & Degree
Yang-yang Qian

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

ESWL Versus ESWL and Endoscopic Treatment

We'll reach out to this number within 24 hrs